Table 2.

Efficacy end points at month 12 (intention-to-treat population)

End PointEverolimus n/N (%)MPA n/N (%)Difference (Everolimus − CNI)95% CI
tBPAR or eGFR<50 ml/min per 1.73 m2
 All patients493 of 1022 (48.2)457 of 1015 (45.1)3.2−1.3 to 7.6
 Tacrolimus-treated patients437 of 914 (47.8)410 of 917 (44.7)3.1−1.6 to 7.7
 CsA-treated patients51 of 100 (51.1)45 of 95 (47.3)3.9−10.3 to 18.0
 Basiliximab-treated patients418 of 849 (49.2)395 of 843 (46.9)2.3−2.5 to 7.2
 rATG-treated patients73 of 171 (42.7)62 of 171 (36.2)6.5−4.2 to 17.1
tBPAR, graft loss, or deatha
 All patients137 of 1022 (14.9)122 of 1015 (12.5)2.3−1.7 to 6.4
 Tacrolimus-treated patients120 of 914 (13.3)104 of 917 (11.9)1.4−1.7 to 4.6
 CsA-treated patients16 of 100 (29.2)15 of 95 (15.9)13.3−13.7 to 40.3
 Basiliximab-treated patients115 of 849 (15.4)107 of 843 (13.3)2.1−2.7 to 6.8
 rATG-treated patients21 of 171 (12.6)15 of 171 (9.0)3.6−3.0 to 10.2
tBPARa
 All patients100 of 1022 (11.5)83 of 1015 (8.8)2.7−1.2 to 6.5
 Tacrolimus-treated patients88 of 914 (10.0)70 of 917 (8.3)1.7−1.1 to 4.5
 CsA-treated patients12 of 100 (26.1)13 of 95 (14.0)12.1−15.8 to 40.0
 Basiliximab-treated patients89 of 849 (12.5)76 of 843 (9.8)2.7−1.9 to 7.3
 rATG-treated patients11 of 171 (6.8)7 of 171 (4.2)2.6−2.3 to 7.6
  • a Kaplan–Meier estimate of incidence rate was used.